Stockscreener 앱 받기
24.12
2.20%
0.52
시간 외 거래:
24.40
0.28
+1.16%
전일 마감가:
$23.60
열려 있는:
$23.45
하루 거래량:
1.39M
Relative Volume:
0.88
시가총액:
$2.95B
수익:
$317.93M
순이익/손실:
$-44.32M
주가수익비율:
-68.04
EPS:
-0.3545
순현금흐름:
$-48.24M
1주 성능:
-10.70%
1개월 성능:
-7.52%
6개월 성능:
+48.80%
1년 성능:
+80.00%
1일 변동 폭
$22.85
$24.56
1주일 범위
$22.85
$28.80
52주 변동 폭
$11.86
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
24.12 | 2.89B | 317.93M | -44.32M | -48.24M | -0.3545 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 개시 | Goldman | Neutral |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis (ARQT) Earnings Call Signals Scaled Growth - TipRanks
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Arcutis (ARQT) director sells 39,272 shares under 10b5-1 plan - Stock Titan
Vanguard Group Inc. Buys 96,991 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 3,687 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Latha Vairavan Sells 2,853 Shares - MarketBeat
Patrick Burnett Sells 6,287 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 37,349 Shares of Stock - MarketBeat
Arcutis (NASDAQ: ARQT) CFO gets RSU, option grants and sells shares - Stock Titan
Arcutis (ARQT) director Watanabe sells shares and receives large option, RSU awards - Stock Titan
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial By Investing.com - Investing.com Australia
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New Trial Launch And Upgraded Revenue Outlook - simplywall.st
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis - Bitget
Arcutis Biotherapeutics Begins Enrollment for Phase 1a/1b Atopic Dermatitis Study - marketscreener.com
Arcutis Biotherapeutics (ARQT) Begins Phase 1 Study of ARQ-234 - GuruFocus
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial - Investing.com
New Arcutis trial tests immune-checkpoint drug for atopic dermatitis - Stock Titan
10 Fastest Growing NASDAQ Stocks to Buy - Insider Monkey
Targets Report: Can Arcutis Biotherapeutics Inc deliver consistent EPS growth2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Masaru Matsuda reports Rule 144 share sales for Arcutis Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) insider sale notice: 3,687 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 37,349 shares after vesting - Stock Titan
Mizuho cuts Arcutis stock price target to $35 on higher costs - Investing.com UK
Arcutis Biotherapeutics (ARQT) insider sale notice: 10,000 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 6.9% After Analyst Downgrade - MarketBeat
ARQT: Mizuho Lowers Price Target but Maintains Outperform Rating - GuruFocus
Mizuho Has Lowered Expectations for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price - MarketBeat
Research Analysts Offer Predictions for ARQT Q1 Earnings - MarketBeat
Precision Trading with Arcutis Biotherapeutics Inc. (ARQT) Risk Zones - Stock Traders Daily
ARQT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Arcutis Biotherapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ARQT) 2026-02-27 - Seeking Alpha
Arcutis execs join TD Cowen health care conference March 2-4 - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $35.00 at Guggenheim - MarketBeat
Guggenheim Raises Price Target for ARQT to $35 | ARQT Stock News - GuruFocus
Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Issues Pessimistic Outlook for ARQT Earnings - MarketBeat
Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference - Bitget
TD Cowen Raises Target Price for Arcutis Biotherapeutics (ARQT) to $35 | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $35.00 Price Target at TD Cowen - MarketBeat
Forecasting The Future: 4 Analyst Projections For Arcutis Biotherapeutics - Benzinga
Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case - Seeking Alpha
ARQT: HC Wainwright & Co. Raises Target Price to $34 in Latest A - GuruFocus
Needham raises Arcutis stock price target to $36 on strong sales - Investing.com Nigeria
H.C. Wainwright raises Arcutis stock price target on strong Zoryve sales - Investing.com Nigeria
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Arcutis Biotherapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Price Target Raised by Needham | - GuruFocus
Earnings call transcript: Arcutis Biotherapeutics Q4 2025 beats expectations By Investing.com - Investing.com Australia
Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):